MDG-1, an Ophiopogon polysaccharide, alleviates hyperlipidemia in mice based on metabolic profile of bile acids

Carbohydr Polym. 2016 Oct 5:150:74-81. doi: 10.1016/j.carbpol.2016.05.008. Epub 2016 May 7.

Abstract

Hyperlipidemia is a chronic metabolic disorder with systemic complications that is prevalent worldwide. MDG-1, a water-soluble β-d-fructan polysaccharide from Ophiopogon japonicas has potent hypolipidemic and weight-control effects. The present study aimed to investigate the effects of MDG-1 on lipid metabolic disorders in diet-induced obese mice based on the metabolic profile of bile acids. C57BL/6 mice were treated with a low-fat diet, high-fat diet or high fat mixed with 1‰ (w/w) MDG-1 diet for 12 weeks. The results showed that MDG-1 inhibited body weight gain and lowered serum and liver total cholesterol contents in obese mice. In addition, MDG-1 could adsorb bile acids in the gut lumen and reduce their reabsorption, thus promoting cholesterol catabolism. Furthermore, MDG-1 inhibited the expression of the farnesoid X receptor, but activated the liver X receptor. Our findings shed new light on the mechanism of MDG-1 in the control of lipids.

Keywords: Bile acids; Dyslipidemia; Nuclear receptors; Polysaccharide; UPLC–MS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bile Acids and Salts / metabolism*
  • Body Weight / drug effects
  • Diet, High-Fat / adverse effects
  • Feces / chemistry
  • Gene Expression Regulation / drug effects
  • Hyperlipidemias / chemically induced
  • Hyperlipidemias / drug therapy*
  • Hyperlipidemias / metabolism*
  • Lipid Metabolism / drug effects
  • Lipids / blood
  • Liver / drug effects
  • Liver / metabolism
  • Metabolomics
  • Mice
  • Mice, Inbred C57BL
  • Ophiopogon / chemistry*
  • Polysaccharides / pharmacology*
  • Polysaccharides / therapeutic use

Substances

  • Bile Acids and Salts
  • Lipids
  • Polysaccharides
  • polysaccharide MDG-1